Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02041481 · ClinicalTrials.gov registry record · Phase 1
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02041481 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 26 participants.
The verdict
NCT02041481, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of MEK inhibitor MEK162 when given together with leucovorin calcium, fluorouracil, and oxaliplatin in treating patients with advanced metastatic colorectal cancer. MEK inhibitor MEK162 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving MEK inhibitor MEK162 with leucovorin calcium, fluorouracil, and oxaliplatin may kill more tumor cells.
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- OTHER pharmacological study
- DRUG leucovorin calcium
- DRUG MEK inhibitor MEK162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02041481
The ClinicalTrials.gov registry entry for NCT02041481 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT02041481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02041481 about?
NCT02041481 is a clinical study titled "MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer". This phase I trial studies the side effects and best dose of MEK inhibitor MEK162 when given together with leucovorin calcium, fluorouracil, and oxaliplatin in treating patients with advanced metastatic colorectal cancer. MEK inhibitor MEK162 may stop the growth of tumor cells by blocking some of th...
What is the current status of trial NCT02041481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-06. Estimated completion is 2018-01-19.
What interventions are being tested in trial NCT02041481?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), pharmacological study (OTHER), leucovorin calcium (DRUG), MEK inhibitor MEK162 (DRUG).
Who is sponsoring clinical trial NCT02041481?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.